Table 1: Clinical and laboratory data of enrolled patients with pulmonary sarcoidosis.

CharacteristicsSarcoidosisRegressionProgressionControls
( = 48)( = 28)( = 20)( = 14)

Age, yrs47.9 (29–72)45.8 (29–70)50.9 (32–72)39.6 (19–63)
Sex (male/female)23/2512/1611/99/5
Smoking (y/n/ex)0/37/110/20/80/17/30/9/5
Pulmonary/pulmonary plus extrapulmonary involvement35/1318/1017/3
CXR stages (I/II)15/3310/185/15
Löfgren’s syndrome (y/n)7/414/243/17
BALF differential count
 % macrophages75.6 ± 5.8
(40.0–94.0)
74.3 ± 6.6
(40.0–94.0)
77.5 ± 4.5
(60.5–87.4)
92.2 ± 13.5
(83.8–97.4)
 % lymphocytes21.6 ± 5.5
(4.6–49.0)
22.8 ± 6.2
(6.0–49.0)
19.9 ± 4.6
(4.6–36.0)
6.2 ± 2.3
(1.6–11.0)
 % neutrophils2.1 ± 1.6
(0.0–18.0)
2.3 ± 1.8
(0.0–18.0)
1.8 ± 1.2
(0.0–10.0)
1.5 ± 0.8
(0.3–6.0)
 % eosinophils1.3 ± 1.9
(0.0–17.3)
1.3 ± 1.6
(0.0–17.0)
1.4 ± 1.9
(0.0–17.3)
0.3 ± 0.1
(0.3–0.6)
 % CD3+#83.6 ± 6.4
(48.0–98.0)
83.8 ± 7.1
(48.0–96.0)
83.3 ± 5.7
(54.0–98.0)
74.1 ± 7.2
(40.0–92.0)
 % CD4+#64.9 ± 8.8
(23.0–92.0)
66.9 ± 8.9
(27.0–92.0)
62.0 ± 8.9
(23.0–86.0)
45.7 ± 7.3
(22.0–67.0)
 % CD8+#16.8 ± 5.7
(2.0–50.0)
14.4 ± 4.9
(2.0–42.0)
20.3 ± 6.4
(4.0–50.0)
27.4 ± 5.5
(14.0–51.0)
 % CD19+#1.03 ± 1.2
(0.0–14.0)
0.9 ± 1.3
(0.0–14.0)
1.2 ± 1.1
(0.0–8.0)
1.2 ± 0.6
(0.0–3.0)
 BALF CD4+/CD8+ ratio6.8 ± 3.6
(0.8–46.0)
7.9 ± 4.2
(1.1–46.0)
5.3 ± 2.6
(0.8–21.3)
2.0 ± 0.5
(0.5–3.7)

BALF: bronchoalveolar lavage fluid; : number of patients; n: no; y: yes; ex: ex-smoker; CXR: chest X-ray; —: not relevant.
Data are presented as mean ± SD (minimum and maximum in parentheses).
Data were not available for four patients.
% of CD3, CD4, CD8, and CD19 refers to total lymphocyte counts.